MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine agonists"

  • 2017 International Congress

    Double-blind, randomized, placebo-controlled, Phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing OFF time in Parkinson’s disease patients with motor fluctuations not well controlled on optimized conventional treatment

    R. Katzenschlager, W. Poewe, O. Rascol, C. Trenkwalder, G. Deuschl, R. Chaudhuri, T. Henriksen, T. van Laar, K. Spivey, S. Vel, A. Lees (Vienna, Austria)

    Objective: The TOLEDO Study (NCT02006121) is a prospective, randomized, multicenter, double-blind, Phase III trial undertaken to investigate the efficacy of apomorphine subcutaneous infusion (APO) compared…
  • 2017 International Congress

    An association between impulse control disorders and dopamine agonists in Japanese patients with Parkinson’s disease.

    Y. Yamanishi, R. Ando, C. Yamasaki, S. Tada, N. Miyaue, H. Iwaki, H. Yabe, N. Nishikawa, M. Nagai, M. Nomoto (Ehime, Japan)

    Objective: To evaluate an association between impulse control disorders (ICDs) and dopamine agonists (DA) therapy in Japanese patients with Parkinson’s disease (PD). Background: ICDs such…
  • 2017 International Congress

    Efficacy of rotigotine as measured by individual Unified Parkinson’s Disease Rating Scale II and III items: a post-hoc analysis

    M. Asgharnejad, H. Pesch, E. Dohin (Raleigh, NC, USA)

    Objective: The key aim was to assess the efficacy of rotigotine (RTG) transdermal patch on individual items of Unified Parkinson’s Disease Rating Scale (UPDRS) II…
  • 2017 International Congress

    Genetic susceptibility associated to impulse control disorders and compulsive behaviors in Parkinson’s disease from a Spanish population.

    S. JESUS, C. TEJERA-PARRADO, C. CORTES, M. BONILLA-TORIBIO, I. BERNAL-BERNAL, M. LABRADOR, L. VARGAS-GONZÁLEZ, M. BERNAL, A. ADARMES, F. CARRILLO, M. CARBALLO, P. GÓMEZ-GARRE, P. MIR (SEVILLA, Spain)

    Objective: Our aim was to identify if there is any difference in the genetic variants linked to an increased susceptibility to suffer impulse control disorders…
  • 2017 International Congress

    Observational study of the effectiveness and tolerability of rotigotine+levodopa therapy in older vs younger Parkinson’s disease patients

    D. Woitalla, M. Asgharnejad, L. Joeres, J.-C. Schuller, K.R. Chaudhuri (Bochum, Germany)

    Objective: Prospective non-interventional study conducted in routine clinical practice (PD0013; NCT02227355) to compare effectiveness and tolerability of rotigotine+levodopa (RTG+Ldopa) in Parkinson’s disease (PD) patients aged…
  • 2017 International Congress

    Alien Limb Syndrome Induced by a Dopamine Agonist in a Patient with Parkinsonism and Agenesis of the Corpus Callosum

    M. Krause, J. Shou, S. Joy, D. Torres-Russotto (Omaha, NE, USA)

    Objective: To examine the case of a patient with parkinsonism and agenesis of the corpus callosum whose alien limb phenomenology ceased after withdrawal from ropinirole.…
  • 2017 International Congress

    Evaluation of rotigotine transdermal patch in combination with low or high dose levodopa in patients with Parkinson’s disease: post-hoc analysis

    E. Dohin, F. Woltering, M. Asgharnejad (Brussels, Belgium)

    Objective: To investigate the value of adding the dopamine agonist (DA) rotigotine (RTG) to low (<400mg/day) or high (≥400mg/day) levodopa (Ldopa) doses in patients with…
  • 2017 International Congress

    Driving license and car accidents in patients with Parkinson’s disease

    M. Tomiyama, T. Ueno, H. Nishijima, T. Kon, R. Haga, Y. Funamizu, A. Arai, C. Suzuki, J. Nunomura, M. Baba (Aomori, Japan)

    Objective: To determine the incidence of and risk factors for car accidents in drivers with Parkinson’s disease (PD). Background: Few studies have addressed traffic accident…
  • 2017 International Congress

    Improving Clinical Trials Through Patient Input: Outcomes of a Partnership Between Pfizer and the Parkinson’s Disease Foundation

    K. Schroeder, M. Fenney, D. Gray, T. Rolph, S. Sohur, V. Todaro (New York, NY, USA)

    Objective: To identify the outcomes of the partnership between Pfizer and the Parkinson’s Disease Foundation (PDF), which was designed to 1. increase understanding of the…
  • 2017 International Congress

    Dopamine Agonists and Postural Disorders in Parkinson’s disease

    L. Ameghino, V. Bruno, M. Merello (Buenos Aires, Argentina)

    Objective: To evaluate the relationship between treatment with DA and the development of postural disorders (CC, PS and AC) in patients with PD.  Background: Stood…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 16
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley